WithdrawnNot Applicable

Evaluation of Pancreatic Duct Stenting in Patients With Pancreatic Pseudocysts.

Stopped: No appropriate participants

Germany0Started 2011-01

Plain-language summary

The disruption of the pancreatic duct seems to be a major cause pseudocyst formation and persistence in patients suffering from acute/chronic pancreatitis. No prospective randomized studies have been conducted on the influence of pancreatic duct stenting for the patients' benefits and recurrence rates. The aim fo this study is therefore to evaluate prospectively in a randomized, controlled fashion in patients wit pancreatic pseudocysts, wether pancreatic duct stenting of a disrupted pancreatic duct is beneficial in terms of quicker clinical recovery and avoidance of recurrence of pancreatic pseudocysts.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * pancreatic pseudocyst, at least 6 cm in diameter * symptomatic pancreatic pseudocyst * increasing size of pancreatic pseudocyst within 6 weeks Exclusion Criteria: * Pregnancy * Age less than 18 years * Postoperative status preventing access to papilla * Allergy to contrast preventing from ERP * Missing informed consent to study * PTT above 1.5 times of normal, unless substituted * Platelet count less than 50.000/µl, unless substituted * Pancreatic ascites or fistula * Life expectancy less than 2 years * Percutaneously drained cysts are not part of the study

What they're measuring

Recurrence of pancreatic pseudocyst

Timeframe: two years

Trial details

NCT IDNCT01276002

SponsorUniversity Hospital Schleswig-Holstein

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-12

View on ClinicalTrials.gov More Chronic Acute Pancreatitis trials